Toxic multinodular goiter screening

Revision as of 18:01, 7 August 2017 by Usama Talib (talk | contribs)
Jump to navigation Jump to search

Toxic multinodular goiter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic multinodular goiter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic multinodular goiter screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic multinodular goiter screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic multinodular goiter screening

CDC on Toxic multinodular goiter screening

Toxic multinodular goiter screening in the news

Blogs on Toxic multinodular goiter screening

Directions to Hospitals Treating Toxic multinodular goiter

Risk calculators and risk factors for Toxic multinodular goiter screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

  • There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

  • According to the [guideline name], screening for [disease name] is not recommended.

OR

  • According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

  • There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

  • According to the [guideline name], screening for [disease name] is not recommended.

OR

  • According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
    • [condition 1]
    • [condition 2]
    • [condition 3]

References

Template:WH Template:WS